Founded in 2016, Canopy Biosciences aims to accelerate the commercialization of life science reagent tools and services through in-licensing key technologies in the fields of genetic engineering and personalized medicine.

For more information, visit Canopy BioSciences or follow their updates on:

Locations

Financials

  • $4.4m
  • 30

Canopy BioSciences Articles

Canopy Biosciences Acquired by Bruker After 4 Years As BioGenerator Incubated Startup

mm
EQ Staff, Jonathan Allen
2 Min Read

In 2019, BioGenerator Invested $3.2 Million in 16 Bioscience Companies in St. Louis

mm
EQ Staff, Jonathan Allen
3 Min Read

BioGenerator’s New Strategies Address St. Louis’ Talent Shortage

EQ admin
< 1 Min Read

Augmented Intelligence Company PercayAI Partners with Canopy Biosciences to Accelerate Drug Development

mm
EQ Staff, Jonathan Allen
< 1 Min Read

Acquisition Gives St. Louis-based Canopy an International Reach

EQ admin
< 1 Min Read

BioGenerator and Kingdom Capital Lead $2.4 Million Series A Round in Canopy BioSciences

mm
EQ Staff, Jonathan Allen
2 Min Read

The Agile Mission of BioGenerator’s Grants Program

mm
EQ Staff, Jonathan Allen
4 Min Read

New Life Science Startup Raises $2 Million

EQ admin
< 1 Min Read